文献速递创伤与烧伤重症综合管理与镇静镇痛

严重创伤后人类T细胞与单核细胞的长期改变:一项探索性横断面研究结果

Trauma-Induced Long-Term Alterations of Human T Cells and Monocytes-Results of an Explorative, Cross-Sectional Study.
PubMed 文献 · Shock · 2020-01-01
一句话结论严重创伤后6个月,患者CD4 T细胞PD-1表达升高、CD4与CD8 T细胞BTLA表达受抑、单核细胞TLR-2/4表达降低,提示免疫抑制表型,但临床感染无差异。

该探索性横断面研究纳入12例伤后6个月(范围-12至+5天)的严重创伤患者(损伤严重度评分≥16)与12名健康志愿者,用流式细胞术定量免疫细胞亚群、表面受体表达及全血刺激后细胞因子分泌。结果:创伤组CD4 T细胞PD-1表达显著升高,CD4与CD8 T细胞BTLA表达显著受抑,单核细胞TLR-2和TLR-4表达及TLR-4单核细胞比例显著降低;HLA-DR密度两组无显著变化;LPS诱导的IL-6与TNF-α分泌呈降低趋势但未达统计学显著;两组临床明显感染无差异。作者认为这些受体改变提示免疫抑制表型,但需进一步研究评估临床意义。

要点

  • 伤后6个月,严重创伤患者(ISS≥16)CD4 T细胞PD-1表达较健康志愿者显著升高,提示免疫抑制表型。
  • 同一队列CD4与CD8 T细胞BTLA表达显著受抑,单核细胞TLR-2和TLR-4表达及TLR-4单核细胞比例显著降低。
  • HLA-DR受体密度两组无显著变化,LPS诱导的IL-6与TNF-α分泌降低但未达统计学显著。
  • 尽管受体改变提示免疫抑制,两组临床明显感染无差异。
  • 作者结论:需进一步研究评估这些免疫改变的临床意义。

适用人群与场景

  • 伤后6个月(范围-12至+5天)的既往严重创伤患者,损伤严重度评分≥16,共12例。
  • 对照为12名健康志愿者。

诊断标准与关键阈值

  • 严重创伤定义:损伤严重度评分≥16。

研究设计与关键结果

  • 探索性横断面研究,纳入12例伤后6个月(范围-12至+5天)的严重创伤患者(ISS≥16)与12名健康志愿者。
  • 创伤组CD4 T细胞PD-1表达较健康志愿者显著升高。
  • 创伤组CD4与CD8 T细胞BTLA表达较健康志愿者显著受抑。
  • 创伤组单核细胞TLR-2和TLR-4表达及TLR-4单核细胞比例显著降低。
  • HLA-DR受体密度两组无显著变化。
  • LPS诱导的IL-6与TNF-α分泌呈降低趋势但未达统计学显著。
  • 两组临床明显感染无差异。

证据类型、等级与局限

  • 证据类型:探索性横断面研究。
  • 局限:作者结论指出需进一步研究评估这些发现的临床意义。

对床旁实践的改变

  • 作者认为伤后6个月严重创伤患者存在CD4与CD8 T细胞及CD14单核细胞表面受体改变,提示免疫抑制表型。
  • 作者指出LPS刺激后IL-6与TNF-α释放虽降低但未达统计学显著。
  • 作者结论:需进一步研究评估这些发现的临床意义。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Major trauma leads to complex immune reactions, known to result in a transient immunodeficiency. The long-term consequences of severe trauma on immune function and regulation as well as its clinical impact remain unclear.

METHODS: Six months (ranging from -12 to +5 days) after a major trauma event, 12 former trauma patients (Injury Severity Score ≥ 16) and 12 healthy volunteers were enrolled. The current clinical status and infection history since discharge were assessed by a standardized questionnaire. Immune cell subsets (cluster of differentiation (CD)4, CD8, CD14), cell surface receptor expression (programmed cell death protein 1 (PD-1), B- and T-lymphocyte attenuator (BTLA), cytotoxic T-lymphocyte-associated protein 4, toll-like receptor (TLR)-2, -4, and -5, Dectin-1, programmed death ligand 1 (PD-1L)), and human leucocyte antigen D-related receptor (HLA-DR)-expression were quantified by flow cytometry. Cytokine secretion (IL-2, -4, -6, -10, and 17A, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ) was assessed after stimulation of whole blood with LPS-, α-CD3/28, or zymosan.

RESULTS: Analysis of surface receptors on T cells revealed a significant elevation of PD-1 expression on CD4 T cells, whereas BTLA expression on CD4 and CD8 T cells was significantly suppressed in the trauma cohort. Monocytes showed a significantly reduced expression of TLR-2 and -4 as well as a reduced proportion of TLR-4 monocytes. HLA-DR receptor density revealed no significant changes between both cohorts. LPS-induced IL-6 and TNF-α secretion showed non-significant trends toward reduced values. No differences regarding clinical apparent infections could be detected.

CONCLUSIONS: Six months following major trauma, changes of cell surface receptors on CD4 and CD8 T cells as well as on CD14 monocytes were present, hinting toward an immunosuppressive phenotype. Following major trauma, although IL-6 and TNF-α release after stimulation were reduced, they did not reach statistical significance. Overall, further studies are necessary to evaluate the clinical implications of these findings.

TRIAL REGISTRATION: DRKS00009876, Internet Portal of the German Clinical Trials Register (DRKS), registration date 11.08.2016, https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00009876.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Ruhrmann S, Schneck E, Markmann M, et al. Trauma-Induced Long-Term Alterations of Human T Cells and Monocytes-Results of an Explorative, Cross-Sectional Study. Shock. 2020. PMID: 30998650. doi:10.1097/SHK.0000000000001358

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。